Renovaro Biosciences Inc. (NASDAQ: RENB) CEO Provides Update on Combination with AI Expert GEDiCube Intl Ltd. in Letter to Shareholders
The agreement with GEDiCube rebrands the company as a wholly-owned subsidiary under the name Renovaro.AI The combined company brings together two innovative platforms in AI and biotherapeutics to offer comprehensive solutions spanning early detection, diagnostic insights, and targeted immunotherapies, for cancer and other diseases The AI division intends to launch commercial products for early cancer detection and improved therapy selection in 2024 – rapidly expanding the largely untapped precision medicine market In September, Renovaro Biosciences (NASDAQ: RENB), an advanced, preclinical biotechnology company focused on cell, gene, and immunotherapy, and GEDiCube Intl Ltd., an AI medical technology company, announced a definitive…